Avenue Therapeutics, Inc.Avenue Therapeutics, Inc.Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪5.82 M‬USD
−1.7809USD
‪−10.38 M‬USD
‪39.43 M‬
Beta (1Y)
−0.46

About Avenue Therapeutics, Inc.

CEO
Alexandra MacLean
Headquarters
Bay Harbor Islands
Employees (FY)
3
Founded
2015
ISIN
US05360L3042
FIGI
BBG00GLTS4V4
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ATXI is 0.1351 USD — it has increased by 2.74% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Avenue Therapeutics, Inc. stocks are traded under the ticker ATXI.
Avenue Therapeutics, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
ATXI stock is 7.50% volatile and has beta coefficient of −0.46. Check out the list of the most volatile stocks — is Avenue Therapeutics, Inc. there?
One year price forecast for Avenue Therapeutics, Inc. has a max estimate of 0.7500 USD and a min estimate of 0.7500 USD.
ATXI earnings for the last quarter are 0.06 USD whereas the estimation was −0.26 USD which accounts for 123.08% surprise. Estimated earnings for the next quarter are −0.10 USD. See more details about Avenue Therapeutics, Inc. earnings.
Yes, you can track Avenue Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ATXI stock has fallen by 9.93% compared to the previous week, the month change is a 15.56% fall, over the last year Avenue Therapeutics, Inc. has showed a 88.93% decrease.
ATXI net income for the last quarter is ‪640.00 K‬ USD, while the quarter before that showed ‪526.00 K‬ USD of net income which accounts for 21.67% change. Track more Avenue Therapeutics, Inc. financial stats to get the full picture.
Today Avenue Therapeutics, Inc. has the market capitalization of ‪5.98 M‬, it has increased by 2.33% over the last week.
No, ATXI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ATXI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Avenue Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
ATXI reached its all-time high on Sep 14, 2020 with the price of 185.0970 USD, and its all-time low was 0.1125 USD and was reached on Feb 7, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 3.00 employees. See our rating of the largest employees — is Avenue Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Avenue Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Avenue Therapeutics, Inc. stock shows the sell signal. See more of Avenue Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Avenue Therapeutics, Inc. future price: according to them, ATXI price has a max estimate of 0.75 USD and a min estimate of 0.75 USD. Read a more detailed Avenue Therapeutics, Inc. forecast: see what analysts think of Avenue Therapeutics, Inc. and suggest that you do with its stocks.